P1, N=300, Enrolling by invitation, M.D. Anderson Cancer Center | Recruiting --> Enrolling by invitation

Resiquimod suppressed B16 melanoma growth, with an effect superior to that of imiquimod...In patient-derived organoids and melanoma slice cultures, resiquimod induced significant tumor killing and CD8+ T cell activation, further augmented by PD-1 antibodies. Our findings support the conclusion that resiquimod promotes CD8+ T-cell priming via dendritic cells and enhances the therapeutic efficacy of anti-PD-1 checkpoint blockade in melanoma.

RrcHSIL non-responders to imiquimod exhibited an even more immunosuppressive microenvironment than complete responders, characterized by increased infiltration of CD4 + FoxP3 + regulatory T cells and (CD14 + )CD68 + CD163 + M2-like macrophages and CD14 + HLADR- monocytic myeloid derived suppressor cells. The limited efficacy of imiquimod in rrcHSIL may be explained by a strong immunosuppressive microenvironment.

P1/2, N=140, Recruiting, United Immunity, co., Ltd. | Not yet recruiting --> Recruiting

DHU-OH-6 enables fluorescence imaging of exogenous and endogenous HOCl in cells and provides fluorescence-guided therapy in an imiquimod-induced psoriasis mouse model, where it alleviates psoriatic skin lesions and mitigates systemic toxicity relative to free CPT. This HOCl-activated hydroxyl drug-release platform offers a generalizable strategy for the design of site-selective, image-guided prodrugs for HOCl-overexpressing diseases.

P2, N=70, Active, not recruiting, Eikon Therapeutics | Recruiting --> Active, not recruiting

Mice were divided into five groups: control (cream base), imiquimod (IMQU; 62.5 mg/day for 7 days), a commonly used inducer of psoriasis-like dermatitis, standard (tacrolimus 20 mg/kg/day, 2 h after IMQU), IMQU + D...These findings suggest that D. tortuosa and D. triradiata NCs possess promising anti-psoriatic potential, through immunomodulatory and anti-inflammatory mechanisms, with D. tortuosa demonstrating superior efficacy. They may serve as effective natural alternatives to conventional psoriasis treatments.

P1/2, N=140, Not yet recruiting, United Immunity, co., Ltd.

P1/2, N=20, Not yet recruiting, Eikon Therapeutics Inc.

P1, N=45, Not yet recruiting, HighField Biopharmaceuticals Corporation

P2/3, N=750, Recruiting, Eikon Therapeutics | Not yet recruiting --> Recruiting

Here, we determined and compared the efficacy of sodium R-lipoate (NaRLA, 50 and 100 mg/kg body weight/day), given orally for 8 consecutive days, in a BALB/c mouse model of imiquimod-induced psoriatic skin inflammation, in comparison with the synthetic drug methotrexate (MTX). Furthermore, NaRLA resulted in a significant improvement (P < 0.001) on both Evans blue extravasation and mast cell degranulation, suggesting a reduction in inflammation and edema. Thus, our observations imply that NaRLA may serve as an effective agent for alleviating psoriatic skin inflammation via targeting IL-23/IL-17A axis and mast cell degranulation.